Status:
UNKNOWN
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH) as T-helper...
Detailed Description
In this phase II trial HLA-A2+ patients with active AML without curative treatment option are vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4 times bi-week...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- AML or myelodysplastic syndromes (MDS)
- Partial response (PR) or complete response (CR) or smoldering course without option for allogeneic stem cell transplantation
- HLA-A2+
- WT1-expression in bone marrow
Exclusion
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00153582
Start Date
April 1 2002
Last Update
February 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology&Oncology Charité CBF
Berlin, Germany, 12200